Get quick answers to your questions about the article from our AI researcher chatbot
{'id': 'https://openalex.org/W2321451013', 'doi': 'https://doi.org/10.3143/geriatrics.39.181', 'title': 'Efficacy and Safety of Combination Therapy with Losartan and Hydrochlorothiazide in Elderly Hypertension.', 'display_name': 'Efficacy and Safety of Combination Therapy with Losartan and Hydrochlorothiazide in Elderly Hypertension.', 'publication_year': 2002, 'publication_date': '2002-01-01', 'ids': {'openalex': 'https://openalex.org/W2321451013', 'doi': 'https://doi.org/10.3143/geriatrics.39.181', 'mag': '2321451013', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/11974942'}, 'language': 'en', 'primary_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.3143/geriatrics.39.181', 'pdf_url': 'https://www.jstage.jst.go.jp/article/geriatrics1964/39/2/39_2_181/_pdf', 'source': {'id': 'https://openalex.org/S2755259892', 'display_name': 'Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics', 'issn_l': '0300-9173', 'issn': ['0300-9173'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4320800702', 'host_organization_name': 'The Japan Geriatrics Society', 'host_organization_lineage': ['https://openalex.org/P4320800702'], 'host_organization_lineage_names': ['The Japan Geriatrics Society'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref', 'pubmed'], 'open_access': {'is_oa': True, 'oa_status': 'bronze', 'oa_url': 'https://www.jstage.jst.go.jp/article/geriatrics1964/39/2/39_2_181/_pdf', 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5100856596', 'display_name': 'Kimika Eto', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I135598925', 'display_name': 'Kyushu University', 'ror': 'https://ror.org/00p4k0j84', 'country_code': 'JP', 'type': 'education', 'lineage': ['https://openalex.org/I135598925']}], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Kimika Eto', 'raw_affiliation_strings': ['Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University.'], 'affiliations': [{'raw_affiliation_string': 'Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University.', 'institution_ids': ['https://openalex.org/I135598925']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5006292446', 'display_name': 'Takuya Tsuchihashi', 'orcid': 'https://orcid.org/0000-0003-2412-1117'}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Takuya Tsuchihashi', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5011639531', 'display_name': 'Isao Abe', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Isao Abe', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5033385933', 'display_name': 'Mitsuo Iida', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Mitsuo Iida', 'raw_affiliation_strings': [], 'affiliations': []}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 1, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': True, 'fulltext_origin': 'pdf', 'cited_by_count': 0, 'citation_normalized_percentile': {'value': 0.0, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 0, 'max': 57}, 'biblio': {'volume': '39', 'issue': '2', 'first_page': '181', 'last_page': '186'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10144', 'display_name': 'Management of Hypertension and Cardiovascular Risk Factors', 'score': 0.953, 'subfield': {'id': 'https://openalex.org/subfields/2705', 'display_name': 'Cardiology and Cardiovascular Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10144', 'display_name': 'Management of Hypertension and Cardiovascular Risk Factors', 'score': 0.953, 'subfield': {'id': 'https://openalex.org/subfields/2705', 'display_name': 'Cardiology and Cardiovascular Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/combination-therapy', 'display_name': 'Combination therapy', 'score': 0.69372386}, {'id': 'https://openalex.org/keywords/hypertension', 'display_name': 'Hypertension', 'score': 0.530667}], 'concepts': [{'id': 'https://openalex.org/C2780361556', 'wikidata': 'https://www.wikidata.org/wiki/Q423930', 'display_name': 'Hydrochlorothiazide', 'level': 3, 'score': 0.9397403}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.9375446}, {'id': 'https://openalex.org/C2780288358', 'wikidata': 'https://www.wikidata.org/wiki/Q410074', 'display_name': 'Losartan', 'level': 4, 'score': 0.9338052}, {'id': 'https://openalex.org/C149323552', 'wikidata': 'https://www.wikidata.org/wiki/Q3090739', 'display_name': 'Ambulatory blood pressure', 'level': 3, 'score': 0.7593291}, {'id': 'https://openalex.org/C84393581', 'wikidata': 'https://www.wikidata.org/wiki/Q82642', 'display_name': 'Blood pressure', 'level': 2, 'score': 0.7215643}, {'id': 'https://openalex.org/C2776999253', 'wikidata': 'https://www.wikidata.org/wiki/Q1304270', 'display_name': 'Combination therapy', 'level': 2, 'score': 0.69372386}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.5477863}, {'id': 'https://openalex.org/C126894567', 'wikidata': 'https://www.wikidata.org/wiki/Q105650', 'display_name': 'Urology', 'level': 1, 'score': 0.48785353}, {'id': 'https://openalex.org/C164705383', 'wikidata': 'https://www.wikidata.org/wiki/Q10379', 'display_name': 'Cardiology', 'level': 1, 'score': 0.45770028}, {'id': 'https://openalex.org/C35785553', 'wikidata': 'https://www.wikidata.org/wiki/Q756720', 'display_name': 'Ambulatory', 'level': 2, 'score': 0.41705933}, {'id': 'https://openalex.org/C134018914', 'wikidata': 'https://www.wikidata.org/wiki/Q162606', 'display_name': 'Endocrinology', 'level': 1, 'score': 0.36210352}, {'id': 'https://openalex.org/C2908929049', 'wikidata': 'https://www.wikidata.org/wiki/Q65963433', 'display_name': 'Angiotensin II', 'level': 3, 'score': 0.3297858}], 'mesh': [{'descriptor_ui': 'D000959', 'descriptor_name': 'Antihypertensive Agents', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D006852', 'descriptor_name': 'Hydrochlorothiazide', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D006973', 'descriptor_name': 'Hypertension', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': True}, {'descriptor_ui': 'D019808', 'descriptor_name': 'Losartan', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D049993', 'descriptor_name': 'Sodium Chloride Symporter Inhibitors', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D000368', 'descriptor_name': 'Aged', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000369', 'descriptor_name': 'Aged, 80 and over', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000959', 'descriptor_name': 'Antihypertensive Agents', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000959', 'descriptor_name': 'Antihypertensive Agents', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D004232', 'descriptor_name': 'Diuretics', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D004334', 'descriptor_name': 'Drug Administration Schedule', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D004359', 'descriptor_name': 'Drug Therapy, Combination', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D005260', 'descriptor_name': 'Female', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006852', 'descriptor_name': 'Hydrochlorothiazide', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006852', 'descriptor_name': 'Hydrochlorothiazide', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D006973', 'descriptor_name': 'Hypertension', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D019808', 'descriptor_name': 'Losartan', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D019808', 'descriptor_name': 'Losartan', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D008297', 'descriptor_name': 'Male', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008875', 'descriptor_name': 'Middle Aged', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D049993', 'descriptor_name': 'Sodium Chloride Symporter Inhibitors', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D049993', 'descriptor_name': 'Sodium Chloride Symporter Inhibitors', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}], 'locations_count': 2, 'locations': [{'is_oa': True, 'landing_page_url': 'https://doi.org/10.3143/geriatrics.39.181', 'pdf_url': 'https://www.jstage.jst.go.jp/article/geriatrics1964/39/2/39_2_181/_pdf', 'source': {'id': 'https://openalex.org/S2755259892', 'display_name': 'Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics', 'issn_l': '0300-9173', 'issn': ['0300-9173'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4320800702', 'host_organization_name': 'The Japan Geriatrics Society', 'host_organization_lineage': ['https://openalex.org/P4320800702'], 'host_organization_lineage_names': ['The Japan Geriatrics Society'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/11974942', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.3143/geriatrics.39.181', 'pdf_url': 'https://www.jstage.jst.go.jp/article/geriatrics1964/39/2/39_2_181/_pdf', 'source': {'id': 'https://openalex.org/S2755259892', 'display_name': 'Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics', 'issn_l': '0300-9173', 'issn': ['0300-9173'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4320800702', 'host_organization_name': 'The Japan Geriatrics Society', 'host_organization_lineage': ['https://openalex.org/P4320800702'], 'host_organization_lineage_names': ['The Japan Geriatrics Society'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'sustainable_development_goals': [{'display_name': 'Good health and well-being', 'id': 'https://metadata.un.org/sdg/3', 'score': 0.72}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W2170369890', 'https://openalex.org/W2158772048', 'https://openalex.org/W2158577494', 'https://openalex.org/W2056149757', 'https://openalex.org/W2051064911', 'https://openalex.org/W2038472506', 'https://openalex.org/W2023313548', 'https://openalex.org/W1997253129', 'https://openalex.org/W1990031109', 'https://openalex.org/W1977955927'], 'abstract_inverted_index': {'本邦における高齢者高血圧へのアンジオテンシンII': [0], '(以下AIIと略す)': [1], '受容体拮抗薬と低用量利尿薬との併用効果を検討した報告は少ない.': [2], 'そこで高齢者高血圧におけるAII受容体拮抗薬と利尿薬との併用の有用性について24時間血圧測定': [3], '(ABPM)': [4], 'を用いて検討した.': [5], '対象は高血圧を有する高齢者14例': [6], '(60~88歳,': [7], '平均75歳).': [8], 'AII受容体拮抗薬': [9], 'losartan': [10, 23, 33, 39], '(25~50mg/日)': [11], 'または': [12], 'hydrochlorothiazide': [13], '(以下HCTZと略す,': [14], '12.5mg/日)': [15], '投与後4週以上経過した症例に対してABPMによる血圧測定を30分間隔で施行し,': [16], '24時間または昼間平均収縮期血圧が140mmHg': [17], '(80歳代では160mmHg)': [18], 'を越える例について両薬剤の併用を開始し,': [19], '4週間後にABPMを再度施行した.': [20], 'また,': [21], '両薬剤併用前後に血液化学検査を施行した.': [22], '先行投与群': [24], '(n=9)': [25], 'における利尿薬併用後の降圧は24時間収縮期/拡張期血圧-19.3±2.3/-6.6±2.3mmHg,': [26], '昼間収縮期/拡張期血圧-21.4±4/-8.4±2.8mmHg,': [27], '夜間収縮期/拡張期血圧-15.2±4/-4.2±2.4mmHgと有意であった.': [28], '一方,': [29], 'HCTZ先行投与群': [30], '(n=5)': [31], 'における': [32], '併用後の降圧も,': [34], '24時間収縮期/拡張期血圧-12.2±4.8/-3.4±1.4mmHg,': [35], '昼間収縮期/拡張期血圧-13.8±6.6/-4±1.1mmHg,': [36], '夜間収縮期/拡張期血圧-10±4.7/-3±2.4mmHgと昼夜を通じて相加的降圧を認めた.': [37], 'HCTZ先行群においては': [38], '追加投与により昼間脈拍数が低下する傾向がみられた.': [40], 'いずれの投与法においても体重,': [41], '腎機能,': [42], '電解質,': [43], '尿酸,': [44], '脂質などに有意な変化を認めなかった.': [45], '高齢者高血圧患者に対し,': [46], 'AII受容体拮抗薬と低用量の利尿薬併用は代謝性および自他覚的副作用を来すことなく相加的降圧効果をもたらし,': [47], '高齢者高血圧の治療に有用と思われた.': [48]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2321451013', 'counts_by_year': [], 'updated_date': '2024-09-15T19:53:12.297505', 'created_date': '2016-06-24'}